Sonoma Pharmaceuticals (SNOA) Accumulated Expenses (2011 - 2025)

Sonoma Pharmaceuticals' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $1.7 million for Q1 2025.

• In Q1 2025, Accumulated Expenses rose 22.41% year-over-year to $1.7 million; the TTM figure through Mar 2025 stood at $1.7 million (up 22.41% YoY), while the FY2025 annual figure was $1.7 million, up 22.41% from the prior year.
• Accumulated Expenses was $1.7 million for Q1 2025 at Sonoma Pharmaceuticals, up from $1.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.7 million in Q1 2025 to a low of $787000.0 in Q1 2021.
• Historically, Accumulated Expenses has averaged $1.3 million across 5 years, with a median of $1.4 million in 2024.
• The sharpest annual moves came in 2021 and 2023: Accumulated Expenses dropped 26.99% in 2021, then surged 38.15% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $787000.0 in 2021, then surged by 34.56% to $1.1 million in 2022, then soared by 38.15% to $1.5 million in 2023, then decreased by 3.01% to $1.4 million in 2024, then rose by 22.41% to $1.7 million in 2025.
• The last three Accumulated Expenses figures came in at $1.7 million (Q1 2025), $1.4 million (Q1 2024), and $1.5 million (Q1 2023), per Business Quant data.